Charles River Laboratories (CRL) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $16.64B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Birgit Girshick |
| IPO Date | 2000-06-23 | CAGR | 11.89% |
| Employees | 19,000 | Website | www.criver.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.01% | Total Yield | 0.01% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $17.47B | P/E | 34.89 | Forward P/E | 27.1 | PEG | — |
| P/S | 2700.65 | P/B | 3820.83 | P/CF | 18670.53 | P/FCF | 29135.78 |
| Sales | $4.00B | Sales 1Y | -0.74% | Sales 3Y | -4.29% | Sales 5Y | 22.16% |
| EPS | $9.9 | EPS 1Y | 264.66% | EPS 3Y | -151.43% | EPS 5Y | -162.5% |
| Sales QoQ | 0.83% | EPS QoQ | -90% | Sales QoQ Avg | -0.68% | EPS QoQ Avg | -197.95% |
| Gross Margin | 32.24% | Operating Margin | 12.35% | Profit Margin | -5.96% | ROCE | 7.72% |
| ROA | -3% | ROE | -8% | Altman Z Score | 2.96 | Piotroski Score | 5 |
| Current Ratio | 1.35 | Quick Ratio | 1.04 | Cash Ratio | 0.17 | Op. CF Ratio | 0.16 |
| Debt/Equity | 1.07 | Debt/Assets | 0.4 | Lt Debt/Equity | 1.07 | Lt Debt/Cap. | 0.48 |
| Intrst Cov. | 4.65 | Inventory Turnover | 7.83 | Asset Turnover | 0.53 | Receivables Turnover | 5.62 |
| Enterprise Value | $17.47B | P/E Ratio | 34.89 |
| Forward P/E | 27.1 | PEG Ratio | — |
| P/S Ratio | 2700.65 | P/B Ratio | 3820.83 |
| P/CF Ratio | 18670.53 | P/FCF Ratio | 29135.78 |
| EPS | $9.9 | EPS Growth 1Y | 264.66% |
| EPS Growth 3Y | -151.43% | EPS Growth 5Y | -162.5% |
| Revenue Growth 1Y | -0.74% | Gross Margin | 32.24% |
| Operating Margin | 12.35% | Profit Margin | -5.96% |
| ROE | -8% | ROA | -3% |
| ROCE | 7.72% | Current Ratio | 1.35 |
| Quick Ratio | 1.04 | Cash Ratio | 0.17 |
| Debt/Equity | 1.07 | Interest Coverage | 4.65 |
| Altman Z Score | 2.96 | Piotroski Score | 5 |
Charles River Laboratories (CRL) valuation & financials
Charles River Laboratories (CRL) has a market capitalization of $16.64B and trades at a price-to-earnings ratio of 34.9. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Charles River Laboratories's revenue grew -0.7% over the last year.
Charles River Laboratories's next earnings report is scheduled for November 4, 2026 before market open (provider scheduled date); analysts estimate EPS of $2.97. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)